Fast Five Quiz: Genetic/Biomarker Testing in Melanoma

Adil Daud, MD


February 22, 2022

The utility of PD-L1 as a biomarker requires further exploration, but it is theorized that immunohistochemistry testing for PD-L1 may help identify patients who are more likely to respond to immune checkpoint inhibitors. High PD-L1 expression (> 5%) may predict equivalent outcomes with nivolumab monotherapy vs combination ipilimumab and nivolumab therapy in patients with unresectable or metastatic melanoma. Low PD-L1 expression, however, may predict worse outcomes with nivolumab monotherapy vs ipilimumab and nivolumab combination therapy. Ultimately, the use of PD-L1 expression cannot yet be used to guide treatment decisions.

Learn more about the workup for malignant melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.